Local interferon therapy for melanoma patients

Area of Science:

• Oncology
• Immunotherapy

Background:

• Malignant melanoma incidence is rising globally.
• Tumor invasion depth is a key prognostic factor in melanoma.
• Advanced melanoma (Clark levels III and IV) presents a significant clinical challenge.

Purpose of the Study:

• To evaluate the efficacy of local r.IFN alpha 2c in treating melanoma patients with Clark levels III and IV.
• To compare survival outcomes between interferon-treated patients and historical control groups.

Main Methods:

• A study involving 27 patients treated with r.IFN alpha 2c and 4 with human natural leukocyte interferon (HNLI).
• Local interferon application was employed.
• Kaplan-Meier and Cox methods were used for statistical analysis, comparing outcomes against historical controls (10 patients with Clark levels III-IV).

Main Results:

• Interferon-treated groups (r.IFN alpha 2c) demonstrated higher survival percentages (60% vs. 25% for Clark III/IV, 40% vs. 33% for Clark IV).
• Statistical analysis at 60 months showed significantly better outcomes in the interferon group (P = 0.0175).

Conclusions:

• While the control group was not randomized, the results suggest r.IFN alpha 2c is a promising treatment for advanced melanoma (Clark levels III and IV).
• Further clinical investigation into r.IFN alpha 2c for melanoma is warranted.